Comments
Alembic Pharmaceuticals on Friday said its joint venture (JV) firm Aleor Dermaceuticals has received approval from the US health regulator for Clobetasol Propionate spray, used to treat plaque psoriasis.
The approved product is therapeutically equivalent to the reference listed drug (RLD) product, Clobex spray, 0.05 per cent of Galderma Laboratories LP.
“Aleor Dermaceuticals has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Clobetasol Propionate Spray, 0.05 per cent,” Alembic Pharmaceuticals said in a regulatory filing.
Clobetasol Propionate Spray, 0.05 per cent is indicated for the treatment of moderate to severe plaque psoriasis.
Quoting IQVIA data, Alembic Pharma said Clobetasol Propionate Spray, 0.05 per cent, has an estimated market size of $22 million for the 12 months ending December 2018.
Alembic has a cumulative total of 103 ANDA approvals (91 final approvals and 12 tentative approvals) from USFDA.
Shares of Alembic Pharma were trading 1.80 per cent higher at Rs 535 apiece on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.